Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3790-3794

  Masciullo, Valeria ^a   Sgambato, Alessandro ^b   Pacilio, Carmen ^a   Pucci, Bruna ^a   Ferrandina, Gabriella ^b   Palazzo, Juan ^a   Carbone, Arnaldo ^b   Cittadini, Achille ^b   Mancuso, Salvatore ^b   Scambia, Giovanni ^b   Giordano, Antonio ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27;

ARTICLE; CANCER RECURRENCE; CANCER SUSCEPTIBILITY; ENZYME DEFECT; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MAJOR CLINICAL STUDY; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIFE TABLES; LOSS OF HETEROZYGOSITY; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 17444427662     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. MacLachlan, T. K., Sang, N., and Giordano, A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr., 5: 127-156, 1995.
2. Tam, S. W., Shay, J. W., and Pagano, M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16/INK4. Cancer Res., 54: 5816-5820, 1994.
3. Hunter, T, and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
4. Kranenburg, O., Scharnhorst, V., Van der Eb, A., and Zantema, A. Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J. Cell Biol., 131: 227-234, 1995.
5. Bullrich, F., MacLachlan, T. K., Sang, N., Druck, T., Veronese, M. L., Allen, S. L., Chiorazzi, N., Koff, A., Heubner, K. Croce, C. M., and Giordano, A. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, PITALRE and a cdk inhibitor, p27kip1, to regions involved in human cancer. Cancer Res., 55: 1199-1205, 1995.
6. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington PC), 269: 682-685, 1995.
7. Catzavelos, C., Bhattacharya, N., Ung, Y., Wilson, J., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K., and Slingerland, J. Decreased levels of the cell cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
8. Porter, P., Malone, K., Haegerty, G., Alexander, G., Gatti, L., Firpo, E., Daling, J., and Roberts, J. Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
9. Loda, M., Cukor, B., Tam, S., Fiorentino, M., Draetta, G., Jessup, J., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
10. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano M., and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
11. Tsihlias, J., Kapusta, L. R., DeBoer, G., Morava-Protzner, I., Zbieranowski, I., Bhattacharya, N., Catzavelos, G. C., Klotz, L. H., and Slingerland, J. M. Loss of cyclin-dependent kinase inhibitor p27 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 542-548, 1998.
12. Erlanson, M., Portin, C., Linderholm, B., Lindh, J., Roos, G., and Landberg, G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas. Prognostic implications. Blood, 92: 770-777, 1998.
13. Guo, Y., Sklar, G. N., Borkowski, A., and Kyprianou, N. Loss of the cyclin-dependent kinase inhibitor p27 protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res., 3: 2269-2274, 1997.
14. Ciaparrone, M., Yamamoto, H., Yao, Y., Sgambato, A., Cattoretti, G., Tomita, N., Monden, T., Rotterdam, H., and Weinstein, I. B. Localization and expression of p27kip1 in multistage colorectal carcinogenesis. Cancer Res., 58: 114-122, 1998.
15. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer Statistics. CA Cancer J. Clin., 46: 5-27, 1996.
16. Weinberg, R. A. Tumor suppressor genes. Science (Washington DC), 254: 1138-1146, 1991.
17. Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R., Boyd, J., and Bast, R. C., Jr. The p53 tumor suppressor gene is altered in gynecologic cancers. Am. J. Obstet. Gynecol., 170: 246-252, 1994.
18. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKenzie, S., Yin, S., and Bast, R. C., Jr. Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087-4091, 1990.
19. Scambia, G., Masciullo, V., Benedetti Panici, P., Marone, M., Ferrandina, G., Todaro, N., Bellacosa, A., Neri, G., Piffanelli, A., and Mancuso, S. Prognostic significance of ras p21 alteration in human ovarian cancer. Br. J. Cancer, 75: 1547-1553, 1997.
20. Barboule, N., Mazars, P., Baldin, V., Vidal, S., Jozan, S., Martel, P., and Valette, A. Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int. J. Cancer, 63: 611-615, 1995.
21. Milde-Langosch, K., Ocon, E., Becker, G., and Loning, T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors. Int. J. Cancer, 79: 612-615, 1998.
22. Giordano, A., Whyte, P., Harlow, E., Franza, B. R., Beach, D., and Draetta, G. A 60 kd cdc2-associated polypeptide complexes with the E1A proteins in adenovirus-infected cells. Cell, 58: 981-990, 1989.
23. Kiyokawa, H., Kineman, R., Manova-Todorova, K., and Koff, A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27kip1. Cell, 85: 721-732, 1996.
24. Fero, M., Rivkin, M., Tasch, M., Porter, P., Carow, C., Firpo, E., Tsai, L., Broudy, V., Perlmutter, R., Kaushansky, K., and Roberts, J. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27kip1 deficient mice. Cell, 85: 733-744, 1996.
25. Erickson, L. A., Jin, L., Wollan, P. C., Thompson, G. B., van Heerden, J., and Lloyd, R. V. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod. Pathol., 11: 169-174, 1998.
26. Resnick, M. B., Schacter, P., Finkelstein, Y., Kellner, Y., and Cohen, O. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod. Pathol., 11: 735-739, 1998.
27. Lloyd, R. V., Jin, L., Quian, X., and Kulig, E. Aberrant p27kip1 expression in endocrine and other tumors. Am. J. Pathol., 150: 401-407, 1997.
28. Yatabe, Y., Masuda, A., Koshikawa, T., Nakamura, S., Kuroishi, T., Osada, H., Takahashi, T., Mitsudomi, T., and Takahashi, T. p27kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res., 58: 1042-1047, 1998.
29. Cote, R. J., Shi, Y., Groshen, S., Feng, A., Cordon Cardo, C., Skinner, D., and Lieskovosky, G. Association of p27kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl. Cancer Inst., 90: 916-920, 1998.
30. Masciullo, V., Scambia, G., Marone, M., Benedetti Panici, P., Giannitelli, C., Ferrandina, G., Bellacosa, A., and Mancuso, S. Altered expression of cyclin D1 and CDK4 in human ovarian cancer. Int. J. Cancer (Pred. Oncol.), 74: 390-395, 1997.
31. Marone, M., Scambia, G., Giannitelli, C., Ferrandina, G., Masciullo, V., Bellacosa, A., Benedetti Panici, P., and Mancuso, S. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int. J. Cancer, 75: 34-49, 1998.
32. Singh, S. P., Lipman, J., Goldman, H., Ellis, F. H., Aizenman, L., Cangi, M. G., Signoretli, S., Chiaur, D. S., Pagano, M., and Loda, M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res., 58: 1730-1735, 1998.
33. Soucek, T., Yeung, R. S., and Hengstschlager, M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2, Proc. Natl. Acad. Sci. USA, 95: 15653-15658, 1998.
34. Tomoda, K., Kubota, Y., and Kato, J. Degradation of the cyclin-dependent-kinase inhibitor p27 kip1 is instigated by Jab1. Nature (Lond.), 398: 160-165, 1999.
35. Yang, R. M., Naitoh, J., Murphy, M., Wang, H. J., Phillipson, J., deKernion, J. B., Loda, M., and Reiter, R. E. Low p27 expression predicts poor-disease free survival in patients with prostate cancer. J. Urol., 159: 941-945, 1998.
36. Shimizu, M., Nikaido, T., Toki, T., and Fujii S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer (Phila.), 85: 669-677, 1999.